| Heading: |
Givinostat |
| Question ID: |
1761334 |
| UIN: |
28289 |
| House: |
Commons |
| Date tabled: |
2025-02-03 |
| Asking Member ID: |
5111 |
| Asking Member display name: |
Martin Wrigley
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Martin Wrigley
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what steps his Department is taking with NHS England to ensure that eligible patients have access to Givinostat employee assistance programmes. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-02-10 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
ITF Pharma UK, the United Kingdom marketing authorisation holder for givinostat, is providing access to givinostat through a type of compassionate use scheme called an Early Access Programme (EAP). Under the EAP, givinostat is free to both patients taking... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |